Skip to content
ES
MARKETS / NASDAQ / NBIX
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP

Neurocrine Biosciences Inc. NBIX

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$2.9B
▲ 21.4% YoY
$478.6M
▲ 40.2% YoY
$748.7M
▲ 34.4% YoY
In brief

What this company does

Neurocrine Biosciences markets FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, and, in collaboration with AbbVie Inc., endometriosis and uterine fibroids. As of December 31, 2025, it had approximately 2,000 full-time employees, primarily based in the U.S. Its sales force in the U.S. numbered approximately 600 professionals focused on neurology, psychiatry, long-term care, and rare diseases. The company's research and development pipeline spans neurology, psychiatry, endocrinology, and immunology. Neurocrine Biosciences was originally incorporated in California in January 1992 and reincorporated in Delaware in May 1996.

Written from the business description in NEUROCRINE BIOSCIENCES INC's annual report to the U.S. Securities and Exchange Commission, filed 11 February 2026. Every sentence was checked against that document before publication.

Growth
USD 2.9B
Revenue, FY2025 · full 17-year series below
Revenue $B Net income $B
FY2025 · Revenue 2.9 · Net income 0.5
1B2B200920112013201520172019202120232025
Compound annual growth
+24.3%
+22.3%
+64.5%
+34.5%
+45.8%
+3.3%
+44.1%
+2.3%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +22.3% a year over five years — but profit grew slower: net income at +3.3%, earnings per share at +2.3%.

The share count rose from 0.09B to 0.10B over the period.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
17 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 21.6% · Net 16.7%
-500%-1000%-1500%200920112013201520172019202120232025
ROE
FY2025 · ROE 16.4%
-500%-1000%200920112013201520172019202120232025
Gross margin98.2%
Operating margin21.6%
Net margin16.7%
Return on assets11.5%
EBITDAUSD 645.1M

Each USD of equity produced 16 cents of profit this year.

Cash & shareholders
USD 38.3M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 748.7
250.0M500.0M-40.0M-80.0M200920112013201520172019202120232025
Net buybacks $M Dividends $M
FY2025 · Dividends — · Net buybacks 38.3
80.0M160.0M-25.0M-50.0M2022202320242025
Dividends paid—
Net buybacksUSD 38.3M
Share of profit8.0%
Consecutive raises—

USD 38.3M in buybacks — 8% of the year's profit went back to shareholders.

Total assetsUSD 4.6B
EquityUSD 3.3B
CashUSD 713.0M
Current ratio3.39×

Equity funds 70% of total assets.

The 17-year record
17 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B2.92.41.91.51.11.00.80.50.20.00.00.00.00.10.10.00.0
Operating income $B0.60.60.30.20.10.20.10.0−0.1−0.1−0.1−0.1−0.00.00.0−0.0−0.1
EBITDA $B0.60.60.30.30.10.20.10.0−0.1−0.1−0.1−0.1−0.00.00.0−0.0·
Income tax $B0.20.10.10.10.0−0.30.00.00.00.00.00.00.00.00.0··
Net income $B0.50.30.20.20.10.40.00.0−0.1−0.1−0.1−0.1−0.00.00.0−0.0−0.1
Free cash flow $B0.70.60.40.30.20.20.10.1−0.1−0.1−0.0−0.0−0.0−0.0−0.00.0−0.1
EPS, diluted $4.673.292.471.560.924.160.390.22−1.62−1.63−1.05−0.81−0.690.080.67−0.15−1.30
Dividend / sh $·················
Payout %·················
ROE %16.414.212.710.07.246.26.64.9−41.5−38.2−28.1−36.8−33.54.794.6−68.4−1290.8
Shares out B0.100.100.100.100.090.090.090.090.090.090.090.080.070.070.060.05·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Compare

This company against its peers

Neurocrine Biosciences Inc.vsAmgen Inc.Same industry: Biological Products, (No Diagnostic Substances)Neurocrine Biosciences Inc.vsGilead Sciences, Inc.Same industry: Biological Products, (No Diagnostic Substances)Neurocrine Biosciences Inc.vsBiogen Inc.Same industry: Biological Products, (No Diagnostic Substances)Neurocrine Biosciences Inc.vsArgenx SESame industry: Biological Products, (No Diagnostic Substances)Neurocrine Biosciences Inc.vsExelixis, Inc.Same industry: Biological Products, (No Diagnostic Substances)Neurocrine Biosciences Inc.vsQiagen N.v.Same industry: Biological Products, (No Diagnostic Substances)Neurocrine Biosciences Inc.vsModerna, Inc.Same industry: Biological Products, (No Diagnostic Substances)
Provenance
Company facts, as filed
How we verify · 0 failures in 66 reconciliationsAUDITED

Reconciled in 17 of 19 fiscal years. 19 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2009

Share this section

Download image